Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
Figure 3
Further analysis of biopsies from the patient with a discordant KRAS mutation status before and after anti-EGFR therapy (#4, see Table 2) showing varying morphology between primary CRC with papillary tissue organization (a) and liver metastasis with tubular tissue organization (b). KRAS mutations analysis of corresponding specimens demonstrate detection of KRAS mutation exon 2 Gly12D (c) in primary CRC whereas an unmutated KRAS status in the liver metastasis was detectable (d). In fluorescence scan and data analysis of CGH only in the liver metastasis biopsied after treatment (f) but not in the primary CRC (e) a decrease in fluorescence of chromosomes 4 and 6 and an increase of chromosome 20 (arrows) could be seen.
